

**Form 51-102F3**  
**Material Change Report**

**1. Name and Address of Company**

AREV Life Sciences Global Corp. (the “Company”)

**2. Date of Material Change**

August 17, 2022

**3. News Release**

A press release was issued on August 17, 2022 and disseminated through Market News and Stockwatch.

**4. Summary of the Material Change**

AREV Corporate Update

**5. Full Description of the Material Change**

VANCOUVER, BC / August 17, 2022 / AREV LIFE SCIENCES GLOBAL CORP. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation AREV Life Sciences Global Corporation announces the appointment of Sateesh Apte MD to the Scientific Advisory Board (the “SAB”) of AREV.

AREV Life Sciences announced the appointment of Sateesh Apte MD to its Scientific Advisory Board, as part of the current scale up for launching clinical studies of SUSTAINN™ for treating Serious Acute Malnutrition in Low & Middle Income Countries. “LMIC”

Dr Apte’s expertise in neurological pathogenesis will complement AREV’s focus on positioning SUSTAINN™ to address the cognitive preservation of children experiencing serious acute malnutrition, which causes brain damage in millions of malnourished children a year. Said Mike Withrow, CEO of AREV Life Sciences Dr. Apte’s appointment to the SAB of AREV is a critical step in successfully designing our studies to demonstrate the clinical value of SUSTAINN in treating SAM.

Dr. Apte specializes in neurology and has an extensive background in research, teaching and consulting in the field of neurological sciences. Dr. Apte’s graduate training was at Haffkine Institute in Mumbai, India, The Pasteur Institute in Paris, France, at Harvard Medical School in Boston and at Stanford University in California. His professional appointments have included active staff positions at the VA Medical Center and Valley Memorial Hospital in Livermore, CA; ValleyCare Medical Center in Pleasanton, CA, and directorships with PainCare Medical Clinic, and the Sleep Disorders Center in San Ramon and Pleasanton, CA. He most recently served as President and CEO of Northern California Physicians Associates, Inc. and Alpha Medical Group, Inc. (1986-1992) He served as President and CEO of ImmunoScience, Inc. in Pleasanton, CA until 2019. Dr. Apte has authored and co-authored a number of articles for medical journals and has several publications pending.

Dr Apte stated “I am very excited to join the AREV SAB as the company commences some of the most important studies in public health for millions of children affected by SAM. The research to attribute the therapeutic effect of SUSTAINN™ promises to be a groundbreaking advance in addressing this leading cause of

pediatric mortality during a global famine, that is exacerbating the burden of infectious diseases in developing nations, which has serious implications for global public health and security”.

Dr Apte’s appointment directly follows a series of meetings at AIDS 2022 with AREV’s corporate leadership, involving representatives of UNAIDS, the World Food Program, USAID, The WHO, NIAID, The MHRP, The Global Fund for AIDS, TB and Malaria, PEPFAR to review concept sheet development of initial studies of SUSTAINN being planned for the 1<sup>st</sup> Q of 2023.

Further, the Company is pleased to announce that the Company has issued 100,000 stock options to Directors, Officers and Consultants of the Company at a price of \$0.12 for a period of 5 years from the issuance dated. These options will vest immediately.

#### About SUSTAINN™

Being developed in collaboration with the Richardson Center for FOOD TECHNOLOGIES AND RESEARCH and leadership at OSU’s Linus Pauling Institute. SUSTAINN™ is a next generation Ready to Use Therapeutic Food designed to provide superior clinical value for patients presenting SAM. SUSTAINN™ is intended to address the dysbiosis, enteropathy and loss of intestinal microbiome which characterizes SAM and the long term cognitive degeneration of SAM patients.

For further information, contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For more information visit [www.arevlifesciences.com](http://www.arevlifesciences.com).

**6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102**

Not applicable.

**7. Omitted Information**

Not applicable.

**8. Executive Officer**

Mike Withrow,  
CEO and Director  
Phone: (778) 379-8551

**9. Date of Report**

August 17, 2022